Cdc42 of the Rho small GTPase family is an intracellular signal transducer that cycles between an inactive GDP-bound form and an active GTP-bound form. 12 Cdc42 has been shown to regulate actin cytoskeleton reorganization, cell migration, proliferation, survival and oncogenesis. [13] [14] [15] [16] By T cell-specific Cdc42 deletion, we have recently found that Cdc42 promotes thymocyte development, peripheral T cell homeostasis and iTreg cells but suppresses T cell activation, Th1
and Th17 cell differentiation, with no effect on Th2 cells. [17] [18] [19] In this study, we aimed to investigate the physiological role of Cdc42 in Th2 cell differentiation and function. We achieved post-thymic deletion of Cdc42 and found that post-thymic deletion of Cdc42 inhibited Th2 differentiation with no effect on Th1, Th17 and iTreg cells. Post-thymic Cdc42 deletion ameliorated Th2-mediated allergic airway inflammation. Pharmacological inhibition of Cdc42 with CASIN, a Cdc42 activity-specific inhibitor, 20 was able to recapitulate the effects of post-thymic deletion of Cdc42 on selective inhibition of Th2 differentiation and on alleviation of allergic airway inflammation. However, CASIN could not ameliorate established allergic airway inflammation.
Thus, Cdc42 emerges as a critical regulator of Th2 cell differentiation and may be a preventive, but not therapeutic target, for asthma.
2 | ME TH ODS
| Mice
Cdc42 flox/flox mice were generated as previously described. 17, 21 Cdc42 flox/flox mice were mated with dLCK iCre transgenic mice, in which
Cre expression is controlled by distal Lck promoter, 22 to generate Cdc42 flox/flox dLCK iCre mice. Mouse genotyping was performed by PCR.
Age-(8-10 weeks) and sex-matched mice were used in each experi- F I G U R E 1 Post-thymic Cdc42 deficiency has no effect on Th1, Th17 and iTreg differentiation. A-C, Naïve CD4 + T cells were differentiated under Th0, Th1 or Th2 conditions for 4 days followed by PMA plus ionomycin restimulation for 5 h, in the presence or absence of BD GolgiPlug ™ at the last 2 h. Cells were processed for CD4 surface staining and IFN-γ and T-Bet intracellular staining and flow cytometry their absolute numbers were not changed ( Figure S1D ).
In the periphery, both the frequency and absolute numbers of 
CD4
+ T cell compartment ( Figure S1F ). Consistent with these results, in vivo BrdU incorporation assay found that CD8 + but not CD4 + T cells in Cdc42 −/− mice underwent homeostatic proliferation (Figure S2A ). In addition, Annexin V/7AAD staining revealed an increased apoptosis in Cdc42 −/− CD8 + but not CD4 + T cells (Figure S2B) . The lack of effect of Cdc42 deletion on CD4 + T cell homeostasis might be due to less efficient deletion of Cdc42 by dLCK iCre whose recombination is known to be less frequent in CD4 + T cells than in CD8 + T cells. 22 We thus performed genotyping of We next evaluated the impact of Cdc42 deficiency on T cell activation and clonal expansion. We found that anti-CD3/CD28-stimulated T cell activation ( Figure S4A ), activation-induced cell death ( Figure S4C ) and clonal expansion ( Figure S5A ) were all significantly downregulated in Cdc42 −/− CD4 + T cells. However, only clonal expansion was impaired in Cdc42 −/− CD8 + T cells ( Figure S5B vs Figure S4B and Figure S4D ).
Therefore, in CD4 + T cells, Cdc42 appears to regulate both cell activation and clonal expansion, whereas in CD8 + cells, Cdc42 regulates clonal expansion but not activation.
| Post-thymic Cdc42 deficiency selectively suppresses Th2 cell differentiation
We then determined whether Cdc42 deletion affected Th and iTreg Figure 3E ). The mRNA levels of these cytokines in the lungs followed similar patterns as protein levels in BAL ( Figure 3F ). Eotaxin and MUC-5AC, two non-T cell-derived mediators of allergic airway inflammation, 24, 31, 32 were also downregulated by Cdc42 deficiency ( Figure 3E,F) . Furthermore, serum OVA-specific IgE was decreased in 3.6 | Pharmacological targeting Cdc42 has no effect on established allergic airway inflammation
We then investigated whether CASIN could ameliorate established allergic airway inflammation. WT mice were immunized and challenged with OVA to induce allergic airway inflammation. Thirty-one days after the last OVA challenge, the mice were re-challenged with OVA and treated with CASIN amid OVA re-challenge ( Figure 7A ). 33 We found that CASIN-and vehicle-treated mice had comparable BAL cells ( Figure 7B ,C), inflammatory cell contents in the lungs (Figure 7D ) and Th2 cytokines and Eotaxin in BAL fluids ( Figure 7E ).
These data suggest that CASIN is not a therapeutic agent for allergic airway inflammation/asthma. 
| DISCUSSION
We have previously shown that thymic deletion of Cdc42 beginning at an early stage of thymocyte development by LCK Cre impaired thymocyte development, peripheral CD4 + and CD8 + T cell homeostasis, and iTreg differentiation but enhanced CD4 + and CD8 + T cell activation and Th1/Th17 cell differentiation with no effect on Th2 cell. [17] [18] [19] In this study, we show that post-thymic deletion of Cdc42 by dLCK iCre had no effect on thymocyte development, CD4 + T cell homeostasis, CD8 + T cell activation, and Th1/Th17/iTreg differentiation, whereas it dampened CD8 + T cell homeostasis, CD4 + T cell activation and Th2 cell differentiation. Because post-thymic deletion of Cdc42 had no effect on thymocyte development and CD4 + T cell homeostasis, ruling out confounding effects of thymic output on T cell homeostasis and of CD4 + T cell homeostasis on CD4 + T cell activation, the defects in CD8 + T cell homeostasis and CD4 + T cell activation suggest that Cdc42 has an intrinsic role in maintaining CD8 + T cell homeostasis and in promoting CD4 + T cell activation. Furthermore, although post-thymic Cdc42 deletion inhibited CD4 + T cell activation, it had no effect on Th1/Th17/iTreg differentiation. The defect in Th2 cell differentiation thus suggests that Cdc42 promotes Th2 differentiation in a Th2 cell-autonomous manner. In this context, the loss of peripheral CD4 + T cells upon thymic deletion of Cdc42 might be attributed to the impaired thymocyte development. The enhanced CD4 + and CD8 + T cell activation might reflect lymphopenia-induced homeostatic activation. However, we do not think that the enhanced Th1/Th17 and weakened iTreg cell differentiation are attributed to the enhanced CD4 + T cell activation, because thymic deletion of Cdc42 had no effect on Th2 cell differentiation. Thus, it is likely that Cdc42 prevents Th1/Th17 and promotes iTreg differentiation in a cell-autonomous manner. Therefore, both However, we did not detect alterations in protein expression of Th1 cytokine IFN-γ and Foxp3 in Cdc42-deficient Th2 cells ( Figure S6D and E), suggesting that the increased mRNA expression of STAT4
and Foxp3 is compensatory effects of the impairment of Th2 differentiation programme that is known to negatively regulate differentiation programme of other T cell lineages. 1 Moreover, we found that Cdc42-deficient Th2 had enhanced 4-1BB signalling and nucleic acid metabolism signalling, suggesting that suppression of the two signalling pathways is important for Cdc42 to promote Th2 cell differentiation. Particularly, as study of genetic deletion of TRAF1 of 4-1BB signalling pathway has suggested that TRAF1 negatively regulates Th2 cell differentiation, 34 it is likely that the increased TRAF1
in Cdc42-deficient Th2 cells contributes to the impaired differentiation and thus Cdc42 promotes Th2 differentiation through repression of TRAF1 expression.
Consistent with its inhibitory effect on Th2 cell differentiation, post-thymic Cdc42 deletion alleviated allergic airway inflammation.
These findings suggest that pharmacological targeting Cdc42 could be beneficial for asthma treatment. However, we found that while Cdc42 inhibitor CASIN suppressed the development of allergic airway inflammation, it had no effect on established allergic airway 
